HMTM - ALZFORUM Overview Name: HMTM Synonyms: LMTM, LMTX, LMT-X, TRx0237, Tau aggregation inhibitor (TAI), Methylene BlueChemical Name: Hydromethylthionine mesylate, Leuco-methylthioninium bis (hydromethanesulfonate)Therapy Type: Small Molecule (timeline) Target Type: Tau (timeline) Condition (s): Alzheimer's Disease, Frontotemporal DementiaU S FDA Status: Alzheimer's Disease (Phase 3), Frontotemporal
TPM (Thy-1 PS1. M146V) | ALZFORUM Brain Res 2004 Aug 13;1017 (1-2):130-6 PubMed Sasmita AO, Ong EC, Nazarenko T, Mao S, Komarek L, Thalmann M, Hantakova V, Spieth L, Berghoff SA, Barr HJ, Hingerl M, Börensen F, Hirrlinger J, Simons M, Stevens B, Depp C, Nave KA Parental origin of transgene modulates amyloid-β plaque burden in the 5xFAD mouse model of Alzheimer's disease
TASTPM (TAS10 x TPM) - ALZFORUM Summary TASTPM is a double transgenic mouse model of Alzheimer’s disease carrying two mutations associated with early onset disease: the Swedish mutation in APP and the M146V mutation in PSEN1 The double transgenic is more commonly used than either of the parental lines (TAS10 and TPM) TASTPM mice develop several AD-related phenotypes, including age-related amyloid pathology and memory
Long-Term Hydromethylthionine Treatment Is Associated with Delayed . . . Bentham P, Staff RT, Schelter BO, Shiells H, Harrington CR, Wischik CM Long-Term Hydromethylthionine Treatment Is Associated with Delayed Clinical Onset and Slowing of Cerebral Atrophy in a Pre-Symptomatic P301S MAPT Mutation Carrier J Alzheimers Dis 2021;83 (3):1017-1023 PubMed Recommends Please login to recommend the paper
APOE c. -286T gt;G (rs405509) | ALZFORUM Sequencing nucleotides −1017 to +406 in samples of 75 unrelated Spanish individuals, the authors identified three new polymorphisms, including c -286T>G, in the APOE promoter Shortly after, c -286T>G was identified in a search for variants that modify the risk of AD associated with APOE4 (Lambert et al , 1998a; Lambert et al , 1998b)
Therapeutics Search | ALZFORUM How would you like to share? Facebook Twitter LinkedIn Back to the Top Find a Therapeutic By Name Go NSC001 AAB-003 AADvac1 AAV-GAD AAV2-BDNF ABBV-1088 ABBV-552 ABBV-916 ABT 418 ABT-089 ABT-288 ABT-384 ABT-957 ABvac40 ACD856 Acetyl-l-carnitine HCI ACI-24 060 ACI-3024 ACI-7104 056 Acitretin ACP-204 ADEL-Y01 Aduhelm AF 102B Affitope AD02 AGB101 AIT-101 AKST4290 AL002 AL003 AL044 AL101 ALIA-1758
Functional assessment staging (FAST) in Alzheimers disease . . . Sclan SG, Reisberg B Functional assessment staging (FAST) in Alzheimer's disease: reliability, validity, and ordinality Int Psychogeriatr 1992;4 Suppl 1:55-69 PubMed Recommends Please login to recommend the paper
MAPT P301S - ALZFORUM J Alzheimers Dis 2021;83 (3):1017-1023 PubMed Rossi G, Conconi D, Panzeri E, Paoletta L, Piccoli E, Ferretti MG, Mangieri M, Ruggerone M, Dalprà L, Tagliavini F Mutations in MAPT give rise to aneuploidy in animal models of tauopathy Neurogenetics 2014 Mar;15 (1):31-40 Epub 2013 Nov 12 PubMed
More Private Funding for Alzheimer’s Research | ALZFORUM Funding also goes to a Phase 1 study of epigallocatechin gallate (EGCG) led by Rafael de la Torre, Hospital del Mar Medical Research Institute, Barcelona, Spain, and a Phase 2 study of a modulator of hepatocyte growth factor, NDX-1017, conducted by Xue Hua of M3 Biotechnology Inc in Seattle
Large Studies Agree: Brain Amyloid Accelerates Cognitive Decline 23 Dec 2014 With the advent of PET amyloid imaging, researchers discovered that as many as a third of cognitively healthy older adults go about their business with brains loaded with amyloid What does this mean for their cognitive future? Are all these people destined to develop Alzheimer’s disease? Initial studies suggested that brain amyloid greatly ramps up the risk for cognitive decline